Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel
January 03 2017 - 7:00AM
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical
company advancing innovative medicines in urology and rheumatology,
today announced that Mary Naggs has been promoted to Vice
President, General Counsel, effective January 1, 2017. Ms.
Naggs will report directly to Richard Pascoe, the Company’s Chief
Executive Officer, and serve as a member of the Company’s executive
team.
Ms. Naggs advances from the position of
Associate General Counsel. Since joining Apricus in 2011, she
has held various roles with increasing responsibility. In her
new role, Ms. Naggs will oversee all legal matters, including
contracts, corporate governance, employment, financing
transactions, compliance and intellectual property.
“Mary’s valuable counsel and unmatched corporate
knowledge and experience have made her an institutional asset,”
says Mr. Pascoe. “She is involved in every aspect of the business
and she has proven her dedication to the Company and our corporate
objectives. We are pleased to have Mary join the executive
team and we are confident she will continue to be a strong and
important leader within our Company while we focus on achieving
profitability through Vitaros® revenue growth and obtaining Vitaros
FDA approval in the United States in 2018.”
Ms. Naggs graduated summa cum laude from Thomas
Jefferson School of Law and she received her bachelor’s degree in
biochemistry and cell biology from Revelle College, University of
California at San Diego.
Ms. Naggs stated, “I truly appreciate the trust
from Rich and the Company’s board of directors that comes with this
promotion to Vice President, General Counsel. I look forward
to leading the legal function and serving on the executive team as
we focus on accomplishing our key objectives in 2017 and
beyond.”
About Apricus Biosciences,
Inc.
Apricus Biosciences, Inc. (APRI) is a
biopharmaceutical company advancing innovative medicines in urology
and rheumatology. Apricus’ commercial product, Vitaros®, for the
treatment of erectile dysfunction, is approved in Canada and
certain countries in Europe, Latin America and the Middle East and
is being commercialized in certain countries in Europe and the
Middle East. In September 2015, Apricus in-licensed the U.S.
development and commercialization rights for Vitaros from Allergan.
Apricus’ marketing partners for Vitaros include Recordati Ireland
Ltd. (Recordati), Ferring International Center S.A. (Ferring
Pharmaceuticals), Laboratoires Majorelle, Bracco S.p.A., Mylan NV
and Elis Pharmaceuticals Ltd. Apricus currently has one active
product candidate, RayVa™, its product candidate for the treatment
of the circulatory disorder Raynaud’s phenomenon.
For further information on Apricus, visit
http://www.apricusbio.com.
*Vitaros® is a registered trademark of NexMed
International Limited. Such trademark is registered in
certain countries throughout the world and pending registration in
the United States.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act, as amended. Statements in this press release that are
not purely historical are forward-looking statements. Such
forward-looking statements include, among other things: references
to potential profitability, Vitaros® revenue growth and potential
Vitaros FDA approval in the United States in 2018. Actual
results could differ from those projected in any forward-looking
statements due to a variety of reasons that are outside the control
of the Company, including, but not limited to: the Company’s
dependence on a number of commercial partners for Vitaros-related
revenue growth in territories outside the United States; the
Company’s ability to address the FDA’s requirements for additional
clinical and pre-clinical data prior to the Vitaros NDA
re-submission; the Company’s ability to raise additional funding
that it may need to continue to pursue its commercial and business
development plans; and the ability to retain key personnel. These
forward-looking statements are made as of the date of this press
release, and the Company assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements. Readers are urged to read the risk factors set forth in
the Company's most recent annual report on Form 10-K, subsequent
quarterly reports filed on Form 10-Q and other filings made with
the SEC. Copies of these reports are available from the SEC's
website or without charge from the Company.
Contact: Matthew Beck
mbeck@troutgroup.com
The Trout Group LLC
(646) 378-2933
Apricus Biosciences, Inc. (NASDAQ:APRI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Apricus Biosciences, Inc. (NASDAQ:APRI)
Historical Stock Chart
From Sep 2023 to Sep 2024